Abbott to Buy Cancer-Screener Exact Sciences for $21 Billion
Affected assets and topics
Why it matters
Abbott Laboratories agreed to acquire cancer-screening company Exact Sciences Corp. for $21 billion, representing a 51% premium to Exact Sciences' closing price before the deal was reported.
Expected market reaction
Market impact analysis based on bullish sentiment with 76% confidence.
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 13211
Original source
Abbott Laboratories agreed to acquire cancer-screening company Exact Sciences Corp., in a deal with a total equity value of about $21 billion. In the biggest health-care deal in two years, Abbott will pay $105 per common share in cash, the companies said Thursday in a statement. The price represents a 51% premium to Exact Sciences’ closing price on Nov. 18, the last full trading day before Bloomberg reported that Abbott was nearing a deal. Bloomberg's Matt Henriksson joins to discuss with Paul Sweeney and Scarlet Fu. (Source: Bloomberg)
Read the full article on Bloomberg
Original article published by Bloomberg on November 20, 2025. Analysis and insights provided by AnalystMarkets AI.
This model on similar stories
Llama 3.1 8B Instant (Groq) · 40.5% correct across 1187 scored calls on indices See the full record